SARS-CoV-2 Neutralizing Antibody Testing for Vaccine Efficacy Assessment
Biodesix and GenScript have come together to offer the cPass™ SARS-CoV-2 Neutralizing Antibody Test as a service, which uses ELISA technology to qualitatively detect neutralizing antibodies to the receptor binding domain (RDB) in the spike protein of SARS-CoV-2. This assay is currently highly applicable for research use to further assess the level of protection that these novel vaccines offer between individuals as well as the appropriate timing required between doses or boosters.
Register for our webinar on May 5, 2021 to:
- Understand the principles of the cPass surrogate virus neutralization test (cPass sVNT) and how it compares to the gold standard live cell virus neutralization tests.
- Learn how cPass sVNT is distinguished from IgG binding antibody assays in delineating between vaccinated individuals and how these data compare with published vaccine efficacy data.
- Understand processes and workflows for integrating cPass sVNT into a high-complexity CLIA laboratory.
- Learn about clinical studies and applications of cPass sVNT in the real-world and for biopharmaceutical research.
Find out more and register.